UNAIDS negotiates lower price for one-pill HIV treatment

UNAIDS on Thursday announced a breakthrough pricing agreement to make the first affordable single-pill HIV treatment regimen available to public sector purchasers in low and middle-income countries (LMICs).
The regimen will be made available to 92 countries in an accelerated treatment rollout as part of efforts to reach the 36.7 million persons living with HIV across the globe.
“Those people will benefit from one of the best medicine we have as a first line. What we are talking about today is a life-changing announcement, it’s about the quality of medicine, but is about equity, it’s about the dignity, it’s about the access to medicine as a human right,” UNAIDS Executive Director Michel Sidibé said.
The generic one-pill one-dose treatment contains dolutegravir (DTG),   widely used in high-income countries and is recommended by the World Health Organisation (WHO).
DTG is considered the best in-class integrase inhibitor and is expected to lower the cost of first-line HIV treatment regimens.
The affordable HIV treatment regimen will be available to LMICs at around a projected average price of US$75 per person per year and will reduce the need for more expensive second- and third-line regimens.
The agreement was announced by the Governments of South Africa and Kenya where the pill is being rolled out in collaboration with UNAIDS and several other agencies.